<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="46345">5-Fluorouracil</z:chebi> (5-FU) and its oral pro-drug <z:chebi fb="0" ids="31348">capecitabine</z:chebi> are widely used in <z:hpo ids='HP_0002664'>oncology</z:hpo> for the treatment of various <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e>, including <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiotoxicity to these drugs is not an uncommon adverse effect and has been reported in 1%-18% of patients </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="31348">Capecitabine</z:chebi> has been reported to trigger mid-apical <z:e sem="disease" ids="C1719712" disease_type="Disease or Syndrome" abbrv="">Takotsubo syndrome</z:e> (TS) </plain></SENT>
<SENT sid="3" pm="."><plain>We describe here the case of a 55-year-old man who presented with cardiogenic shock and ECG signs of ST-elevation <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The symptoms began 28 h after the commencement of <z:chebi fb="0" ids="31348">capecitabine</z:chebi> adjuvant therapy, following a radical right-sided hemicolectomy for low-differentiated <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the caecum </plain></SENT>
<SENT sid="5" pm="."><plain>Echocardiography showed severe global left ventricular dysfunction </plain></SENT>
<SENT sid="6" pm="."><plain>Cardiac magnetic resonance imaging showed no signs of late <z:chebi fb="0" ids="33375">gadolinium</z:chebi> enhancement </plain></SENT>
<SENT sid="7" pm="."><plain>These clinical, cardiac image study findings and the course of the disease with full recovery within one week were consistent with global TS triggered by the adjuvant therapy <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and presenting with a life-threatening cardiogenic shock </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, we have demonstrated the speedy dynamic of the left ventricular wall motion abnormality with global TS at presentation and basal (inverted) TS findings 4 days later on </plain></SENT>
</text></document>